Epigenetic synergy between decitabine and platinum derivatives

Area of Science:

• Epigenetics
• Cancer Biology
• Pharmacology

Background:

• Aberrant epigenetic silencing of tumor suppressor genes drives cancer development.
• Epigenetic drugs like decitabine are effective in myeloid leukemia but have limited efficacy in solid tumors and can lead to resistance.
• There is a need to identify synergistic combinations to improve the clinical efficacy of decitabine.

Purpose of the Study:

• To screen approved anti-cancer drugs for synergistic combinations with decitabine.
• To investigate the epigenetic mechanisms underlying drug synergy.
• To explore the potential of decitabine-platinum compound combinations in cancer therapy.

Main Methods:

• Utilized the YB5 cell line, a derivative of SW48 colon cancer cells, to screen for drug-induced gene reactivation and synergy with decitabine.
• Tested 16 approved anti-cancer drugs in combination with decitabine.
• Performed genome-wide studies to analyze gene expression, DNA methylation, and histone modifications.

Main Results:

• Platinum compounds, such as carboplatin, demonstrated striking synergy with decitabine in reactivating silenced genes, including GFP, MLH1, and PDLIM4.
• The combination therapy showed dose-dependent and combination-schedule-dependent synergy.
• Genome-wide analyses revealed enhanced reactivation of hypermethylated genes and altered histone modifications (H3K4 trimethylation, H3K9 acetylation) with reduced methyl-binding protein occupancy.

Conclusions:

• The combination of decitabine with platinum analogs exhibits significant epigenetic synergy.
• This synergistic effect involves modulation of histone modifications and methyl-binding protein occupancy.
• The findings suggest that decitabine-platinum compound combinations hold potential for treating various cancers.